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HZ Work Group Interpretation of RZV Safety Data
 ~12 M doses RZV doses distributed in the U.S.
 Reports of reactogenicity-like symptoms-- consistent with RCTs
 Preliminary statistical signals for Bell’s Palsy and Guillain-Barré syndrome (GBS)
2
Validated 
cases 
Administrative cases
Events Reported through VAERS C
ER
TA
IN
TY
HZ Work Group Interpretation of RZV Safety Data
 ~12 M doses RZV doses distributed in the U.S.
 Reports of reactogenicity-like symptoms-- consistent with RCTs
 Preliminary statistical signals for Bell’s Palsy and Guillain-Barré syndrome (GBS) 
3
Validated 
cases 
Administrative cases
Events Reported through VAERS C
ER
TA
IN
TY
HZ Work Group Interpretation of RZV Safety Data
 ~12 M doses RZV doses distributed in the U.S.
 Reports of reactogenicity-like symptoms-- consistent with RCTs
 Preliminary statistical signals for Bell’s Palsy and Guillain-Barré syndrome (GBS) 
4
Validated 
cases 
Administrative cases
Events Reported through VAERS C
ER
TA
IN
TY
HZ Work Group Interpretation of RZV Safety Data
 ~12 M doses RZV doses distributed in the U.S.
 Reports of reactogenicity-like symptoms-- consistent with RCTs
 Preliminary statistical signals for Bell’s Palsy and Guillain-Barré syndrome (GBS) 
5
Validated 
cases 
Administrative cases
Events Reported through VAERS C
ER
TA
IN
TY
Investigation of Bell’s Palsy following RZV- VAERS
 No signal in VAERS
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Investigation of Bell’s Palsy following RZV- Admin cases
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 ↑ RR in VSD
 No ↑ RR with other comparison 
groups
 No signal in VAERS
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Investigation of Bell’s Palsy following RZV- Validated cases
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 15 of 36 (42%) cases validated
 RR= 1.3 in VSD
 No ↑ RR with other 
comparison groups
 No signal in VAERS
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Investigation of GBS following RZV- VAERS
 No signal in VAERS
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 ↑RR in VSD & Medicare
 Lower RR with concurrent 
comparators
 No signal in VAERS
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Investigation of GBS following RZV- Validated cases
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 Validated GBS: RZV=2,  ZVL=2
 Risk difference for RZV-ZVL: 
4.7-5.9 cases/100,000 py
 ↑RR, large confidence intervals
 ↑RR in VSD & Medicare
 Lower RR with concur compar.
 No signal in VAERS
Summary of HZ Work Group Discussions
 GBS is rare and interpretation of elevated risk of GBS is uncertain given only 2 
validated cases in RZV and ZVL groups
 Due to wide confidence intervals that overlap baseline rates, current data are 
insufficient to determine if a safety problem exists
 HZ Work Group members agree that there is insufficient evidence at this time to 
support a change in policy or practice 
 HZ Work Group agrees with the proposed next steps:
–
–
–
Continue enhanced monitoring and clinical case review of Bell’s Palsy and GBS 
reports following RZV in VAERS
Continue to track and chart validate cases of Bell’s Palsy and GBS in VSD
Chart validate GBS cases in Medicare and pursue self-controlled analytic options
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Outcome #4: Serious adverse events
Estimates of effect (ZOE-50 and ZOE-70)
Outcome No. of subjects (# studies)
No. reported in 
controls (%)
No. reported in 
vaccinated (%) Difference
Serious adverse
event*
29,311 
(1)
1,900 
(13.0%)
1,842 
(12.6%) 0.4%
Serious adverse 
events considered 
related to vaccine**
29,311 
(1)
15
(0.1%)
15 
(0.1%) 0.0%
• The remaining 7 studies administered HZ/su to a total of 616 participants and found no serious 
adverse events related to vaccination
*Throughout study period (mean follow up =  4 yrs)
**ZOE-50:  The three serious adverse events (SAE) considered to be related to vaccination by the investigators in the HZ/sugroup were immune 
thrombocytopenic purpura, musculoskeletal chest pain, and nervous system disorder.
**ZOE-70:  the SAEs considered by the investigator to be related to the trial intervention in the HZ/sugroup were lymphadenitis, acute myocardial infarction, 
ulcerative colitis, acute pancreatitis, administration-site erythema, administration-site pain, chills, pyrexia, allergic granulomatous angiitis, bacterial arthritis, 
erysipelas, herpes zoster oticus, eczema, neutropenic sepsis, and acute myeloid leukemia. Some participants had more than one event. One death in t  su
group was considered by the local investigator to be related to the vaccination. 14
Outcome #5: Reactogenicity (Grade 3 rxn§)
Estimates of effect (ZOE-50 and ZOE-70)
Outcome No. of subjects(# studies)
No. reported in 
controls (%)
No. reported in 
vaccinated (%) Difference
Any Grade 3 reaction* 9,936 (1)
155 
(3.1%)
820 
(16.5%) 13.4%
Grade 3 injection-
site reaction**
9769 
(1)
17
(0.3%)
460 
(9.4%) 9.1%
Grade 3 systemic
reaction**
9762 
(1)
116 
(2.4%)
528 
(10.8%) 8.4%
§“Grade 3 injection site = redness and swelling at injection site >100 mm or preventing normal activity
Grade 3 systemic = temperature (oral) >39oC or preventing normal activity
*Solicited and unsolicited report of a Grade 3 reaction within 7 days after vaccination
** Solicited report of Grade 3 reaction within 7 days after vaccination
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